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Summary A prospective, randomized, controlled, multi-centre clinical
trial was performed to test the effectiveness of an antimicrobial central
venous catheter (CVC) made of polyurethane integrated with silver,
platinum and carbon black (Vantexw). Adults expected to require a CVC
for more than 60 h were eligible, and were randomized to receive the test or
control catheter. All CVCs were inserted with new venipunctures using full
aseptic technique. Following catheter removal, the distal tip and an
intracutaneous segment were removed and cultured using semiquantitative
and quantitative methods. Peripheral blood samples were obtained and
cultured to confirm cases of catheter-related bloodstream infection (CRBSI).
Bacterial and fungal organisms were identified by standard microbiological
methods. Catheter placement was performed primarily in the intensive care
unit (50%) or operating theatre (42%). Complete data could be evaluated for
539 patients (77%). The mean duration of CVC placement was 149.3 h (six
days). There were no significant differences in colonization or bacteraemia
rates between the test and control catheters. The overall colonization rate
was not particularly low (24.5%), and yet CVC-related bacteraemia occurred
in only 1.4% of patients, and CRBSI occurred in only one patient from the
control group (0.2%). Insertion site and dressing change frequency were
significantly associated with the colonization rate. Although CVCs with
antimicrobial features have been associated with a decrease in catheterrelated colonization and bacteraemia, this study demonstrated that
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infection rates may depend more on non-catheter-related factors, such as
adherence to infection control standards, selection of insertion site,
duration of CVC placement, and dressing change frequency. As microbial
resistance increases, clinicians should make maximal use of these processes
to reduce catheter-related infections.
Q 2005 The Hospital Infection Society. Published by Elsevier Ltd. All rights
reserved.

Introduction
Central venous catheters (CVCs) are essential for
many critically ill patients, and the prevention of
central line infections is vitally important. In the
USA, approximately five million CVCs are inserted
annually.1 US Centers for Disease Control and
Prevention (CDC) data have shown central-lineassociated bloodstream infection rates of 5.3 per
1000 catheter-days.2 There have been reports of
catheter colonization rates greater than 50%,3 and
catheter-related bloodstream infections (CRBSIs)
occur with 3–8% of catheters.4 Given an estimated
15 million central-line-days annually in intensive
care units, approximately 16 000 patients experience CRBSI each year.2 Catheter-related infections
increase patient morbidity, prolong hospitalization
and raise mortality rates.5 These infections are also
associated with higher costs (increases from $6000
to over $90 000 for those with CRBSI).4,6–9
Risk factors for CRBSI include patient characteristics (e.g. age and immunity), technique-related
variables, and features of devices.10 The CDC has
recommended several techniques to reduce the risk
of catheter-related infection. Foremost are meticulous aseptic procedures, including careful cleansing of the insertion site and the use of maximal
barrier precautions.5,11 In recent years, there has
been a concerted effort to apply antimicrobial
technology to prevent infections, including the use
of prophylactic antibiotics and catheters with
special coatings and surface modifications.12,13
CVCs with chlorhexidine-silver sulphadiazine (CSS)
or minocycline-rifampicin coatings have been
associated with significant reductions in CRBSI.3,14
However, adverse reactions to chlorhexidine have
been reported,10,15–17 and there are concerns
related to potential antibiotic resistance with
regard to rifampicin.14,16 These concerns and
other technical issues may limit the widespread
use of antibiotic-coated catheters.
The Vantexw CVC with Oligone (Edwards Lifesciences, Irvine, CA, USA) is made of polyurethane
integrated with silver, platinum and carbon black.

It was designed to reduce the risk of bacterial
colonization on catheter surfaces. Oligon was
reported to be effective against both Gram-positive
and Gram-negative bacteria, including strains commonly associated with device-related infections in
in vitro studies.12,13 The purpose of this study was to
determine whether the Vantex CVC lowers the
incidence of catheter colonization and CRBSI
compared with a standard CVC (MultiMed w;
Edwards Lifesciences), and to evaluate other
factors that impact on CVC infection rates.

Methods
Patient enrolment
This study was designed as a prospective, randomized, controlled, open-label, multi-centre clinical
trial. Ten investigational sites obtained institutional review board approval and informed consent prior to patient enrolment. Adults expected to
require a CVC for more than 60 h were eligible.
There were no eligibility constraints related to
diagnoses, hospital unit, or anticipated treatments
or procedures. Patients were excluded if: they had
a history of allergic reactions to silver, platinum or
carbon black; were expected to live for seven days
or less; had evidence of a burn or dermatitis at the
catheter insertion site; were pregnant or lactating;
or had a catheter placed in the same proposed site
previously. A computer-generated randomization
schedule was used to avoid potential bias in
catheter selection. However, due to the difference
in appearance of the CVCs, blinding could not be
achieved. Determinations for inclusion were made
at individual sites, and patients were enrolled from
May 2000 until April 2001.

Catheter insertion and maintenance
The test and control catheters had similar designs
(polyurethane 7-French, triple-lumen CVCs). All
CVCs were inserted using full aseptic technique

Impact of CVC type and methods on catheter-related colonization and bacteraemia
(sterile gown, sterile gloves, masks and large sterile
drapes), based on published guidelines by the CDC
for insertion of CVCs.5 Patients received only one
study catheter, and all CVCs were inserted through
new venipunctures. Guidewire exchanges were not
permitted. Patients were assessed daily for indications of infection, and dressing changes were
performed according to local hospital policies.
CVCs were removed when no longer required for
patient care, when the patient experienced an
adverse event, or when catheter exchange was
necessary.

Definitions
The definitions of catheter colonization and CRBSI
published by the CDC were used.5 Colonization was
defined as the growth of 15 or more colony-forming
units (CFUs) in cultures of catheter tips or segments
prepared by the roll-plate method (semiquantitative) or more than 1000 CFUs by the sonication
method (quantitative). CRBSI was defined as the
isolation of the same organism (i.e. identical
species) from the colonized catheter and peripheral
blood in a patient with accompanying clinical signs
and symptoms of bloodstream infection (BSI) and no
other apparent source of BSI.5 Since a diagnosis of
CRBSI relies on clinical judgment, we used bacteraemia as another category to document cases
where the same organism was isolated from the
catheter and peripheral blood cultures, regardless
of documented signs and symptoms or other
potential sources of infection. This definition for
bacteraemia has recently been used by other
investigators.1,18–20

141

Statistical analysis
Sample size was determined based on the scientific
literature and in vitro studies, which indicated that
2% of the test group and 7% of the control group
were expected to experience CRBSI. In addition, it
was anticipated that 15% of the patients would be
non-evaluable. Therefore, to achieve 90% power
with an alpha of 0.05 (i.e. for there to be a 90%
chance of detecting a difference significant at the
5% level), 400 patients were required in each
treatment group. Frequencies and percentages
were calculated for categorical variables. Descriptive statistics were calculated for continuous
variables. Comparisons of test and control groups
were performed using the Wilcoxon rank-sum test
for continuous variables and Fisher’s exact test for
ordinal variables. In addition, Chi-square analyses
were performed to determine differences between
patients with and without CFUs. Where appropriate, a Cochran-Armitage test was used to assess
increasing or decreasing rates across categories.
Multiple logistic regression was used to obtain
estimates of the adjusted odds ratios for factors
independently associated with colonization. Spearman rank correlation was used to calculate the
correlation between colonization and bacteraemia.
All statistical testing was two-sided and an alpha
level of 0.05 was used to determine significance.
Each analysis was reported separately, with no
adjustment for multiple comparisons. All statistical
analyses were performed in SAS (Version 8.0, SAS
Institute, Cary, NC, USA).

Results

Cultures and antimicrobial susceptibility

Patient demographics and characteristics

Following catheter removal, the distal tip and a 3mm intracutaneous segment were aseptically cut
from the catheter and placed in individual containers for microbial evaluation. A core laboratory
(Esoterix, Inc., San Antonio, TX, USA) was used to
ensure consistency when performing and evaluating
roll-plate, sonication and blood cultures. Both
semiquantitative and quantitative methods were
used for all samples, which adheres to the CRBSI
diagnostic criteria recently used by other researchers.21 Aerobic and anaerobic blood cultures were
performed. Gram stains were performed on blood
cultures suspected of being positive and on all
isolates from CVC cultures. Bacterial and fungal
organisms recovered were identified by standard
microbiological methods.

In total 699 patients were enrolled at 10 investigational sites before an interim analysis revealed that
there were no differences in colonization or CRBSI
rates between the test and control groups. At that
time, it was determined that enrolment would have
to be tripled to obtain a sufficient sample size,
given the extremely low overall CRBSI rate. Therefore, enrolment in the trial was discontinued.
Data could be evaluated for 539 patients (77%).
Patients were excluded from analysis when the CVC
was inadvertently contaminated or discarded (64
catheters), or when samples were transported to
the core laboratory more than 24 h after CVC
removal. There were no significant differences in
patient characteristics between the evaluable (266
control, 273 test) and non-evaluable (83 control,
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77 test) groups. The mean duration of CVC placement was 149.3 h (6.2 days) for evaluable and
136.9 h (5.7 days) for non-evaluable patients.
For the evaluable patients, the test and control
groups were similar in demographics and patient
characteristics (Table I). Both groups had similar
indications for CVC placement and removal. Catheter placement was performed primarily in the
intensive care unit (50%) or operating theatre (42%);
8% were inserted in other units. More than 70% of
catheters in both groups were removed because the
CVC was no longer required. Approximately 15% of
patients in both groups had clinical signs or
symptoms of infection (e.g. oedema, erythema,
skin irritation, tenderness, purulent drainage,
increased white blood cell count, increased heart
rate or fever) that led to the decision to remove the
catheter. In most cases, cultures of the catheter
and peripheral blood samples failed to confirm
catheter-related bacteraemia or infection. In 16
cases (3%), the catheter was removed after the
patient’s death.

Catheter-related colonization and infection
Quantitative cultures were positive more frequently than semiquantitative cultures, and 24.5%
of all samples were colonized according to at least
one definition (Table II). Among colonized catheters, the most frequent genus isolated was
Staphylococcus (isolated on O15% of the catheters
in both groups). The most common species of
Staphylococcus were S. epidermidis (11.6% control
and 12.1% test) and S. aureus (2.6% control and 1.5%
test). Other bacteria cultured were Enterococcus
Table I

Patient characteristics

Sex (male)
Age (years)
Antibiotic use within seven days
Trauma within 30 days
Surgery within 30 days
Urinary catheter
Other intravascular catheter
Mechanical ventilation
Immunosuppressive therapy
Corticosteroid use
Total parenteral nutrition
Diabetes
Cardiovascular disease
Pulmonary disease
Gastrointestinal disease
Neurological disorder

Control %
NZ266

Test %
NZ273

63.5
55.2
73.9
29.7
43.6
89.1
80.8
77.1
7.1
9.0
10.1
21.4
62.0
38.0
44.0
28.6

56.8
55.4
79.0
28.2
40.3
90.5
79.1
78.4
5.9
9.9
8.4
19.4
62.6
44.7
46.2
30.0

faecalis, Pseudomonas aeruginosa, S. capitis,
S. haemolyticus and S. warneri (1–2% of patients
in each group). Candida was found in fewer than 1%
of cases. There were no significant differences in
colonization rates between test and control groups.
Initially, only patients with clinical signs or
symptoms of infection had peripheral blood
samples drawn. However, after 331 patients were
enrolled, no CRBSI cases had been detected.
Therefore, the protocol was revised to require
peripheral blood samples to be drawn upon catheter removal, regardless of clinical signs and
symptoms of infection. All 368 patients enrolled
subsequently had blood cultures drawn within 4 h of
catheter removal. Of the patients positive for
colonization by any criterion, there were only four
control patients (1.5%) and three test patients
(1.2%) with a genus/species match between the
catheter tips or segments and peripheral blood
samples (i.e. bacteraemia cases). Only one patient
(control group) with bacteraemia also showed
clinical signs of infection. Thus, during the entire
trial, CRBSI occurred in just 0.2% of patients. There
were no cases of CVC-related sepsis.

Factors associated with colonization
The duration of CVC placement was greater than
60 h for most patients (92%). There was a linear
relationship between duration of CVC placement
and colonization rate (Figure 1). Although the
confidence intervals (CIs) for each of the individual
categories overlap, the trend was significant with
increasing time (PZ0.021).
Colonization rates differed significantly by insertion site (Figure 2). The colonization rates for the
right internal jugular (31%) and both subclavian
sites (left 15%; right 27%) were significantly below
(P!0.05) that for the left internal jugular (53%).
There were too few femoral cases to permit
statistical comparisons. Approximately equal proportions of test and control catheters were used at
each insertion site [e.g. right internal jugular vein
(44.4% test; 46.9% control); right subclavian vein
(18.4% test; 22.3% control)].
The mean time between dressing changes was
two days for both groups (range 1–15 days). Patients
receiving dressing changes more frequently than
every six days had a colonization rate of approximately 25%. For patients with dressing change
intervals of six days or more, the colonization rate
increased to 35% (PZ0.0013; odds ratio 1.84, 95% CI
1.27–2.68). There were no significant differences in
colonization rates by sex or hospital unit (intensive
care unit versus operating theatre). Colonization
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Table II
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Central venous catheter infection analysis by core laboratory

Tip—roll plate R15 CFUs
Tip—sonication O1000 CFUs
Segment—roll plate R15 CFUs
Segment—sonication O1000 CFUs
Samples with any colonization (of tips or
segments by roll plate or sonication)
Bacteraemia
Catheter-related bloodstream infection
Bacteraemia per 1000 catheter-days

Control % NZ262

Test % NZ252

All patients % NZ514a

16.0
5.0
18.7
11.5
24.4

13.1
5.6
15.1
11.1
24.5

14.6
5.3
16.9
11.3
24.5

1.5
0.4
2.59 per 1000

1.2
0.0
1.79 per 1000

1.4
0.2
2.18 per 1000

CFU, colony-forming unit.
a
These data include only those patients for whom samples of both catheter tips and segments were submitted to the core laboratory.

rates ranged from 0% to 50% by investigational site,
and the difference was not significant (PZ0.9).
Multi-variate logistic regression analysis also
confirmed that insertion site and dressing change
frequency contributed independently to the risk of
colonization. Specifically, the odds ratio for subclavian compared with internal jugular was 0.45
(95% CI 0.29–0.70). This indicated that the risk of
CVC colonization with a subclavian insertion site
was approximately one-half that where the internal
jugular site had been used.

Discussion
CVC-related infections pose a substantial risk to
patient health and constitute a large economic
burden. This clinical trial was designed to test the
effectiveness of a CVC made of polyurethane
integrated with silver, platinum and carbon black,
and to evaluate other factors that influence CVC
infection rates. Unexpectedly, we found no significant differences in colonization or bacteraemia
rates between the test and control catheters. The

Figure 1 Percentage of central venous catheters
(CVCs) colonized by duration of CVC placement. The
error bars indicate 95% confidence intervals. The trend of
increasing colonization with increasing duration of CVC
placement is statistically significant (PZ0.021).

overall colonization rate was 24.5%, yet CVCrelated bacteraemia occurred in only 1.4% of
patients, and CRBSI occurred in just one patient
(0.2%).
Several factors may have contributed to the low
rate of bacteraemia observed in our study. These
include relatively short duration of CVC placement,
more frequent use of subclavian or internal jugular
insertion sites (rather than femoral), the high rate
of antibiotic usage, and the prohibition of guidewire
exchange. With regard to duration of CVC placement, 109 patients (20%) had CVCs for 60–95 h and
332 patients (62%) had CVCs for O96 h, so there was
ample time for colonization and CRBSI to develop in
most patients. In the present study, insertion site
was an independent predictor of colonization, and
subclavian sites had less colonization than internal
jugular or femoral sites. This is consistent with
other recent reports.14,19,22,23 More important
perhaps was strict adherence to infection control
procedures by participating clinicians. A recent
review concluded that these methods are essential
when using intravascular catheters.10 The protocol
used for the present study required that CVC
insertion be performed in accordance with CDC
guidelines for infection control (i.e. using strict

Figure 2 Percentage of central venous catheters
(CVCs) colonized by insertion site. The error bars indicate
95% confidence intervals.
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aseptic technique with maximal barrier precautions). In addition, all catheters were inserted
through new venipunctures, and guidewire
exchanges were not allowed.
Two other trials have studied the Vantex
catheter. Ranucci et al. reported the results of a
similar multi-centre trial comparing the Vantex
catheter with control CVCs coated with benzalkonium chloride (evaluable NZ545). The overall
colonization rate (24%) was nearly identical to
our findings, but the overall CRBSI rate was much
higher than found in our study (3.8% vs 0.2%).24 A
recent randomized trial by Corral et al.25 evaluated
the Vantex CVC compared with a standard polyurethane CVC. These investigators reported a
statistically significant difference in CRBSI and
colonization rates between test and control catheters (CRBSI: 1% test, 4% control; tip colonization:
15% test, 28% control). The higher CRBSI rates
reported by Corral et al. may be due in part to the
longer duration of CVC placement in that study
(mean duration of CVC placement was 13 days)
compared with others (e.g. nine days for Ranucci
et al. and six days in our study). Another factor that
may have contributed to the difference is that
Corral et al.’s study was confined to a higher risk
population (intensive care unit patients only). It is
possible that a device made from a novel antimicrobial material would reveal its greatest benefit
in higher risk populations with a longer duration of
CVC placement.
The link between colonization and bacteraemia
may be weaker than previously thought. Polderman
and Girbes suggested that approximately 20% of
colonized catheters proceed to catheter-related
bacteraemia.8 Although this seems true overall,
there is wide interstudy variability. Veenstra et al.
performed a meta-analysis involving 13 studies
comparing colonization and bacteraemia rates in
CVCs coated with CSS with uncoated CVCs.3
Veenstra et al. found the overall bacteraemiacolonization ratio was 25%, but the range was 0–
86%. The correlations between colonization and
bacteraemia in these studies were only 0.25 and
0.22 for CSS-coated and uncoated catheters,
respectively. However, the correlation between
bacteraemia rates for the two types of catheters
was 0.86. These correlations imply that the
association between colonization and bacteraemia
is much weaker than that of the intrastudy
bacteraemia rates. Thus, factors inherent to the
study appear to exert more influence on bacteraemia rates than the observed rate of colonization.
These findings are based on a small number of
studies, but they suggest that the causal linkage
between colonization and bacteraemia may need
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re-examination. Indeed, Maki et al. stated that
CRBSI rates, rather than colonization rates, are the
preferred measure when comparing CVCs.4
These results should be interpreted considering
the limitations of this study. Patient populations
were heterogeneous and not limited to patients
prone to a high risk of infection. Most patients with
bacteraemia were identified after the protocol
change requiring peripheral blood cultures to be
performed on every patient. It should be noted that
many of the analyses performed for this study were
ad hoc, and should therefore be considered
exploratory and serve to generate hypotheses.
Additional studies are needed to understand the
relative contributions of various factors, perhaps
including variables such as the site of insertion.
This trial evaluated the antimicrobial effectiveness of a CVC that integrates silver, platinum and
carbon black, as well as other factors that influence
colonization and CRBSI. Despite colonization rates
that were not particularly low in either the test or
control groups, both groups had low rates of
catheter-related bacteraemia. The causal relationship between colonization and bacteraemia may be
weaker than reported previously. Although other
CVCs with antimicrobial features have been associated with a decrease in catheter-related colonization and bacteraemia, this study demonstrated that
infection rates may depend more on non-catheterrelated factors, such as insertion site, duration of
CVC placement, dressing change frequency and
guidewire exchange. Antimicrobial catheters may
have a place in critical care, particularly in cases
where the CVC is anticipated to be left in place for
more than six days. In an era of increasing microbial
resistance, it is even more important to identify and
use non-pharmacological methods to reduce infection. Whenever possible, clinicians should consider
using aseptic technique with maximal barrier
precautions, subclavian insertion sites, and
reduced duration of CVC placement with more
frequent dressing changes to reduce the risk of
CRBSI.
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